PL2314609T3 - Pochodne metastyny i ich zastosowanie - Google Patents

Pochodne metastyny i ich zastosowanie

Info

Publication number
PL2314609T3
PL2314609T3 PL09803004T PL09803004T PL2314609T3 PL 2314609 T3 PL2314609 T3 PL 2314609T3 PL 09803004 T PL09803004 T PL 09803004T PL 09803004 T PL09803004 T PL 09803004T PL 2314609 T3 PL2314609 T3 PL 2314609T3
Authority
PL
Poland
Prior art keywords
metastine derivatives
metastine
derivatives
Prior art date
Application number
PL09803004T
Other languages
English (en)
Inventor
Taiji Asami
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL2314609T3 publication Critical patent/PL2314609T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09803004T 2008-07-30 2009-07-29 Pochodne metastyny i ich zastosowanie PL2314609T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008196598 2008-07-30
EP09803004.2A EP2314609B1 (en) 2008-07-30 2009-07-29 Metastin derivative and use thereof

Publications (1)

Publication Number Publication Date
PL2314609T3 true PL2314609T3 (pl) 2017-07-31

Family

ID=41610461

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09803004T PL2314609T3 (pl) 2008-07-30 2009-07-29 Pochodne metastyny i ich zastosowanie

Country Status (14)

Country Link
US (1) US20110212890A1 (pl)
EP (2) EP3210998A1 (pl)
JP (1) JP5698977B2 (pl)
CY (1) CY1118975T1 (pl)
DK (1) DK2314609T3 (pl)
ES (1) ES2617657T3 (pl)
HR (1) HRP20170319T1 (pl)
HU (1) HUE030900T2 (pl)
LT (1) LT2314609T (pl)
PL (1) PL2314609T3 (pl)
PT (1) PT2314609T (pl)
SI (1) SI2314609T1 (pl)
SM (1) SMT201700131T1 (pl)
WO (1) WO2010013762A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275433B1 (en) * 2008-04-30 2017-06-07 Kyoto University Metastin derivative and use thereof
JP5455661B2 (ja) 2009-01-29 2014-03-26 ギガフォトン株式会社 極端紫外光源装置
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
CA3038865A1 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating female infertility
TW202000196A (zh) * 2018-03-01 2020-01-01 日商石原產業股份有限公司 保存安定性優異之醫藥組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規g蛋白質共役型レセプター蛋白質、そのdnaおよびそのリガンド
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
AU1889101A (en) * 1999-12-17 2001-06-25 Takeda Chemical Industries Ltd. Process for producing kiss-1 peptide
WO2001075104A1 (fr) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Nouvelle proteine, adn codant pour celle-ci, et son procede de production
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
DE60219645T2 (de) * 2001-09-19 2007-08-09 Takeda Pharmaceutical Co. Ltd. Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
AU2003201854A1 (en) * 2002-01-11 2003-07-30 Takeda Chemical Industries, Ltd. PROCESS FOR PRODUCING KiSS-1 PEPTIDE
AU2003272964A1 (en) * 2002-10-09 2004-05-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
WO2004063221A1 (ja) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
JP4804714B2 (ja) * 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
US6800611B2 (en) 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
US7754220B2 (en) * 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
WO2005117939A2 (en) * 2004-04-23 2005-12-15 Applied Research Systems Ars Holding N.V. Use of gpcr54 ligands for the treatment of infertility
WO2006001499A2 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2007084211A2 (en) * 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20070244048A1 (en) * 2006-03-20 2007-10-18 Marsh Donald J Neuromedin U receptor agonists and uses thereof
US20100215637A1 (en) * 2006-03-28 2010-08-26 Biopharmica Ltd Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof
JP5279021B2 (ja) 2006-04-26 2013-09-04 国立大学法人京都大学 Gpr54アゴニスト活性を有する新規化合物
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
JP4906476B2 (ja) 2006-11-06 2012-03-28 株式会社ブリヂストン タイヤ加硫モールドの洗浄方法
JP2009058102A (ja) 2007-09-03 2009-03-19 Akebono Brake Ind Co Ltd パッドクリップ及び多板ディスクブレーキ
CA2701612A1 (en) * 2007-10-05 2009-04-09 Takeda Pharmaceutical Company Limited Neuromedin u derivative

Also Published As

Publication number Publication date
EP2314609A4 (en) 2013-01-16
ES2617657T3 (es) 2017-06-19
CY1118975T1 (el) 2018-01-10
HRP20170319T1 (hr) 2017-05-05
DK2314609T3 (en) 2017-03-13
SI2314609T1 (sl) 2017-05-31
EP2314609B1 (en) 2016-11-30
WO2010013762A1 (ja) 2010-02-04
US20110212890A1 (en) 2011-09-01
EP3210998A1 (en) 2017-08-30
EP2314609A1 (en) 2011-04-27
SMT201700131T1 (it) 2017-05-08
PT2314609T (pt) 2017-03-06
JPWO2010013762A1 (ja) 2012-01-12
LT2314609T (lt) 2017-04-10
HUE030900T2 (en) 2017-06-28
JP5698977B2 (ja) 2015-04-08

Similar Documents

Publication Publication Date Title
NL300891I2 (nl) Lotilaner en zouten daarvan
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
HRP20190016T1 (hr) Heterociklički spojevi i njihova upotreba
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
PL2281006T3 (pl) Środki łączące i ich zastosowania
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0906980A2 (pt) Composição de derivados e maleatados
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
CR20130360A (es) Compuesto heterocíclico y su uso
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
ATE518837T1 (de) Indazolamidderivate
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
DK2318378T3 (da) Quinazolin-derivater
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0918328B8 (pt) composição e artigo
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0922652A2 (pt) Derivados de quinazolinamida
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate